Sellas Life Sciences is trading 4.4% down at $11.80 following online commentary suggesting a potential delay in the release of its Phase 3 REGAL trial data for acute myeloid leukemia (AML).
- Shares are reacting to social media speculation from Martin Shkreli, who predicted that the AML data release may be pushed back to Christmas, contradicting the company's previous summer guidance.
- The uncertainty regarding the timeline for the company’s lead asset is weighing on investor sentiment and the overall outlook for the clinical program.